Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Evogene (EVGN) over the last 13 years, with Q2 2025 value amounting to -$2.3 million.

  • Evogene's Cash from Operations fell 14218.15% to -$2.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.0 million, marking a year-over-year decrease of 3206.91%. This contributed to the annual value of $19.7 million for FY2024, which is 19130.09% up from last year.
  • Evogene's Cash from Operations amounted to -$2.3 million in Q2 2025, which was down 14218.15% from -$5.2 million recorded in Q1 2025.
  • In the past 5 years, Evogene's Cash from Operations registered a high of $8.1 million during Q4 2021, and its lowest value of -$7.7 million during Q1 2022.
  • For the 5-year period, Evogene's Cash from Operations averaged around $407555.6, with its median value being $1.2 million (2022).
  • As far as peak fluctuations go, Evogene's Cash from Operations tumbled by 26436.34% in 2022, and later soared by 36251.66% in 2023.
  • Over the past 5 years, Evogene's Cash from Operations (Quarter) stood at $8.1 million in 2021, then crashed by 127.93% to -$2.3 million in 2022, then skyrocketed by 362.52% to $5.9 million in 2023, then decreased by 23.02% to $4.6 million in 2024, then plummeted by 150.45% to -$2.3 million in 2025.
  • Its Cash from Operations was -$2.3 million in Q2 2025, compared to -$5.2 million in Q1 2025 and $4.6 million in Q4 2024.